Seqens

Seqens

X

Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_29375

DSSTox_CID_29375
Developments
Full Screen View

DSSTox_CID_29375

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

16 Suppliers, 4 USDMF, 6 CEP/COS, 2 JDMF, 3 EU WC, 2 KDMF, 12 NDC API, 13 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

DOSSIERs // Finished Dosage Forms

101 Dossiers, 30 FDA Orange Book, 38 Europe, 32 Canada, 1 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;INJECTION - 0.25%, INJECTABLE;INJECTION - 0.25%;0.0091MG/ML, INJECTABLE;INJECTION - 0.5%, INJECTABLE;INJECTION - 0.5%;0.0091MG/ML, INJECTABLE;INJECTION - 0.75%, INJECTABLE;INJECTION - 0.75%;0.0091MG/ML, INJECTABLE;INJECTION - 0.25%, INJECTABLE;INJECTION - 0.5%, INJECTABLE;INJECTION - 0.5%;0.0091MG/ML, INJECTABLE;INJECTION - 0.75%, INJECTABLE;INJECTION - 0.75%;0.0091MG/ML, INJECTABLE;INJECTION - 4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML), INJECTABLE;INJECTION - 4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML), INJECTABLE;INJECTION - 0.5%;0.0091MG/ML, INJECTABLE;INJECTION - EQ 0.02MG BASE/ML;2%, INJECTABLE;INJECTION - EQ 0.01MG BASE/ML;2%

RELATED EXCIPIENT COMPANIES

Suppliers, 4 Actylis, 1 Nanjing Well Pharmaceutical, 1 Pfanstiehl

GLOBAL SALES INFORMATION

26 Finished Drug Prices

26 Finished Drug Prices

MARKET PLACE

24 APIs, 3 DOSSIERS // FDF

ANALYTICAL SOLUTION(s)

6 EDQM Standards, 1 USP Standards, 2 JP Standards, 1 Other Ref. Standards

DIGITAL CONTENT

9 News

9 News

PharmaCompass

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

ALK

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ALK and Grandpharma Team Up to Market the First Adrenaline Autoinjector in China

Details:

Jext® is expected to be the first AAI to market in China. Prior to registration in mainland China, Grandpharma plans to start selling Jext® in southern China under a special licence linked to the existing registration of Jext® in Hong Kong.

Lead Product(s): Epinephrine Bitartrate

Therapeutic Area: Immunology Product Name: Jext

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Grandpharma

Deal Size: $14.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 30, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY